

Resource Summary Report

Generated by [NIF](#) on Aug 9, 2026

COSMIC - Catalogue Of Somatic Mutations In Cancer

RRID:SCR_002260

Type: Tool

Proper Citation

COSMIC - Catalogue Of Somatic Mutations In Cancer (RRID:SCR_002260)

Resource Information

URL: <http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>

Proper Citation: COSMIC - Catalogue Of Somatic Mutations In Cancer (RRID:SCR_002260)

Description: Database to store and display somatic mutation information and related details and contains information relating to human cancers. The mutation data and associated information is extracted from the primary literature. In order to provide a consistent view of the data a histology and tissue ontology has been created and all mutations are mapped to a single version of each gene. The data can be queried by tissue, histology or gene and displayed as a graph, as a table or exported in various formats.

Some key features of COSMIC are:

- * Contains information on publications, samples and mutations. Includes samples which have been found to be negative for mutations during screening therefore enabling frequency data to be calculated for mutations in different genes in different cancer types.
- * Samples entered include benign neoplasms and other benign proliferations, in situ and invasive tumours, recurrences, metastases and cancer cell lines.

Abbreviations: COSMIC

Synonyms: Catalogue Of Somatic Mutations In Cancer

Resource Type: database, data or information resource

Defining Citation: [PMID:20952405](#)

Keywords: cancer, mutation, somatic mutation, tumor, cancer genome, genome, gene, dna, tissue, histology, bio.tools, FASEB list

Related Condition: Cancer

Funding: Wellcome Trust 077012/Z/05/Z

Availability: Free

Resource Name: COSMIC - Catalogue Of Somatic Mutations In Cancer

Resource ID: SCR_002260

Alternate IDs: nif-0000-02690, biotools:cosmic, OMICS_00082

Alternate URLs: <http://www.sanger.ac.uk/perl/CGP/cosmic>, <https://bio.tools/cosmic>

Record Creation Time: 20220129T080212+0000

Record Last Update: 20260808T190352+0000

Ratings and Alerts

No rating or validation information has been found for COSMIC - Catalogue Of Somatic Mutations In Cancer.

No alerts have been found for COSMIC - Catalogue Of Somatic Mutations In Cancer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4809 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gurjao C, et al. (2026) Germline Predisposition to Oncogenic Alkylating Damage in Colorectal Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 35(3), 420.

Robinson E, et al. (2026) STK11 mutations and deletions define a distinct subtype of cervical adenocarcinoma. medRxiv : the preprint server for health sciences.

Culliford R, et al. (2026) Contrasting Features of Papillary and Chromophobe Renal Cell Carcinoma Revealed by Whole-Genome Sequencing. Molecular cancer research : MCR, 24(5), 327.

Pregnall AM, et al. (2026) Metastatic progression of pheochromocytoma and paraganglioma occurs via parallel evolution. NPJ precision oncology, 10(1).

Botticelli A, et al. (2026) The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 45.

Huang KK, et al. (2026) Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence. *Cancer discovery*, 16(3), 497.

Chen J, et al. (2026) A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1652.

Chang HY, et al. (2026) Uniform Processing of Diverse Sequencing Data: A Cross-Population Comparison of Colon Cancer Genomic Landscapes from The Cancer Genome Atlas and a Chinese Cohort. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 35(5), 762.

Kojima M, et al. (2026) Precision Oncology for Pediatric Solid Tumors Using In-Hospital Pediatric/AYA Malignancy-Specific Panel Sequencing. *Cancer science*, 117(3), 797.

Huffman BM, et al. (2026) A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1666.

Vlachos G, et al. (2026) Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility. *British journal of cancer*.

Lee JK, et al. (2026) The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2653.

van der Elst A, et al. (2026) Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(13), 2732.

Swift SZ, et al. (2026) Integration of Short- and Long-Read RNA Sequencing Enables the Discovery of Circular RNAs. *Cancer research*, 86(5), 1300.

Tirtei E, et al. (2026) Mapping Genomic Heterogeneity in Pediatric and Adolescent-Young Adult Sarcomas: Insights from the Italian SAR-GEN2016 and SAR-GEN_ITA Prospective Multicenter Trials. *Cancer research communications*, 6(4), 857.

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. *Cancer research*, 86(4), 1073.

Lee JB, et al. (2026) Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer. *ESMO open*, 11(2), 106057.

Hang JF, et al. (2026) Out-of-frame CBX3::ALK fusion drives ALK activation and therapy response. *Cell reports. Medicine*, 7(4), 102697.

Chang LJ, et al. (2026) Assessment of Circulating Tumor DNA for Early Detection of Hepatocellular Carcinoma in Alpha-Fetoprotein-Negative Patients With Cirrhotic Nodules. JGH open : an open access journal of gastroenterology and hepatology, 10(1), e70331.

Kawazu M, et al. (2026) Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges. Cancer research communications, 6(4), 961.